Meridian Bioscience, Inc. (VIVO) Misses Q4 EPS by 2c; Reaffirms FY12 Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $5.87 --0%
Financial Fact:
DILUTED EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
MAYS, CRMT, REPL, More
Financial Fact:
DILUTED EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $40.27 million versus the consensus estimate of $43.29 million.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
